Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Résumé Rhea-AI

Connect Biopharma (Nasdaq: CNTB) a annoncé des résultats de Phase 3 de RADIANT-AD pour rademikibart, présentés à l’AAD 2026. Lors d’un essai de 52 semaines (n=259), rademikibart a atteint des réponses durables : EASI-75 96.6%, IGA 0/1 87.1% et EASI-90 85.3%, avec une sécurité comparable à celle du placebo et de faibles taux de conjonctivite.

L’étude a utilisé 300 mg SC toutes les deux semaines, avec une phase d’induction de 16 semaines et une phase d’entretien de 36 semaines ; la société organisera un webcast et une conférence téléphonique le 30 mars 2026.

Positif

• Réponse EASI-75 de 96.6% à la Semaine 52
• IGA 0/1 (clear/almost clear) atteint par 87.1% à la Semaine 52
• Réponse EASI-90 de 85.3% à la Semaine 52
• Profil de sécurité comparable à celui du placebo avec de faibles taux de conjonctivite
• Efficacité durable maintenue sur 52 semaines

Négatif

• Étude menée uniquement en Chine avec 259 patients, limitant la généralisation à l’échelle mondiale

Market Reaction – CNTB

-21.16% $2.72 5.0x vol

15m delay 41 alerts

-21.16% Since News

$2.72 Last Price

$2.56 $3.62 Day Range

-$41M Valuation Impact

$152.06M Market Cap

5.0x Rel. Volume

Following this news, CNTB has declined 21.16%, reflecting a significant negative market reaction. Our momentum scanner has triggered 41 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $2.72. This price movement has removed approximately $41M from the company's valuation. Trading volume is very high at 5.0x the average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Study duration: 52 weeks Patients enrolled: 259 patients Dose regimen: 300 mg q2w SC +5 more

8 metrics

Study duration 52 weeks Phase 3 RADIANT-AD atopic dermatitis trial

Patients enrolled 259 patients Adolescent and adult moderate-to-severe AD in China

Dose regimen 300 mg q2w SC Rademikibart dosing in 16-week induction phase

EASI-75 responders 96.6% ≥75% reduction in EASI at Week 52 among Week 16 responders

IGA 0/1 87.1% Clear/almost clear with ≥2-point reduction at Week 52

EASI-90 responders 85.3% ≥90% reduction in EASI at Week 52 among Week 16 responders

Prior exposure Over 1,500 participants Completed studies across indications with no significant drug-related safety issues

Conference call time 8:00 a.m. ET Company-hosted call and webcast on March 30, 2026

Market Reality Check

Price: $3.46 Vol: Volume 338,256 is 1.64x t...

high vol

$3.46 Last Close

Volume Volume 338,256 is 1.64x the 20-day average of 205,848, indicating elevated trading ahead of/into this update. high

Technical Shares at $3.46 are trading above the 200-day MA of $2.08 and within 9.4% of the 52-week high at $3.82.

Peers on Argus

Scanner data flags a stock-specific move: CNTB’s momentum direction is listed as...

2 Down

Scanner data flags a stock-specific move: CNTB’s momentum direction is listed as up, while peers in momentum like IFRX and ATRA are down ~2.7–2.8%. Broader biotech peers listed (COYA, OVID, STTK, VXRT) mostly show declines, reinforcing that this reaction is not part of a sector-wide upswing.

Previous Clinical trial Reports

5 past events · Latest: Mar 10 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 10	Phase 3 AD data preview	Positive	+5.3%	Announced upcoming AAD presentation of Phase 3 rademikibart AD results with strong NDA basis.
Aug 14	Asthma education & trials	Positive	-8.9%	Expanded asthma education program and highlighted ongoing Phase 2 Seabreeze STAT asthma studies.
May 14	Phase 2 COPD start	Positive	+1.2%	Initiated FDA‑approved Phase 2 Seabreeze STAT COPD study of rademikibart in acute exacerbations.
May 13	Phase 2 asthma start	Positive	-5.2%	Initiated Phase 2 Seabreeze STAT asthma study after prior data showed rapid lung function gains.
Mar 31	Positive Phase 2 asthma	Positive	+4.0%	Published positive global Phase 2 asthma trial results, enabling FDA agreement to move to Phase 3.

Pattern Detected

Clinical-trial headlines have produced mixed reactions: several positive data/initiations aligned with gains, but others, including sizable program updates, saw notable selloffs, indicating inconsistent trading around rademikibart news.

Recent Company History

Over the past year, CNTB has steadily advanced rademikibart across multiple indications. On Mar 31, 2025, positive global Phase 2 asthma data supported advancement to Phase 3. In May 2025, the company initiated Phase 2 Seabreeze STAT trials in asthma and COPD, followed by an asthma education initiative in Aug 2025. On Mar 10, 2026, CNTB highlighted that Phase 3 AD results would be presented at AAD with a strong basis for an NDA in China. Today’s detailed 52-week AD data build directly on that earlier read-through.

Historical Comparison

-0.7% avg move · In the past 5 clinical‑trial headlines, CNTB’s average move was -0.71%, with both rallies and sellof...

clinical trial

-0.7%

Average Historical Move clinical trial

In the past 5 clinical‑trial headlines, CNTB’s average move was -0.71%, with both rallies and selloffs. Today’s -6.5% reaction to detailed, positive Phase 3 AD data skews more negative than typical.

Historical clinical‑trial news traces rademikibart from positive Phase 2 asthma data into Phase 2 Seabreeze STAT asthma/COPD programs and now robust 52‑week Phase 3 atopic dermatitis results, indicating a broad, multi‑indication development arc.

Market Pulse Summary

The stock is dropping -21.2% following this news. A negative reaction despite positive data fits CNT...

Analysis

The stock is dropping -21.2% following this news. A negative reaction despite positive data fits CNTB’s mixed history around clinical headlines, where some favorable rademikibart updates preceded selloffs. The reported 52-week durability and high response rates contrast with the -6.5% move, suggesting profit taking or positioning dynamics rather than clearly adverse fundamentals. With shares still above the $2.08 200-day MA, traders may reassess as additional detail and management commentary are digested.

Key Terms

phase 3, atopic dermatitis, eczema area and severity index, investigator’s global assessment, +4 more

8 terms

phase 3 medical

"today announced results from a Phase 3 52-week study in patients with moderate‑to‑severe atopic dermatitis"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

atopic dermatitis medical

"Phase 3 52-week study in patients with moderate‑to‑severe atopic dermatitis (AD)"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

eczema area and severity index medical

"achieved a ≥75% reduction from baseline in the Eczema Area and Severity Index (EASI‑75)"

A standardized clinical score that measures how much skin is affected by eczema and how severe the lesions are, combining area and intensity into one number much like a report card for a skin condition. Investors care because changes in this score are often used as a primary measure of a treatment’s effectiveness in clinical trials, influencing regulatory approval chances, market potential, and the perceived value of companies developing eczema therapies.

investigator’s global assessment medical

"achieved a score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction on the Investigator’s Global Assessment of Atopic Dermatitis (IGA 0/1)"

A clinician’s overall rating of a patient’s condition or how well a treatment is working during a clinical trial, usually expressed on a simple scale (for example: clear, mild, moderate, severe). Think of it as a coach giving a single score that sums up a player’s performance rather than listing every statistic. Investors watch this measure because it is often used as an official trial endpoint that can drive regulatory decisions, market expectations, and a drug’s commercial prospects.

subcutaneous medical

"rademikibart administered via subcutaneous (SC) injection every 4 weeks worked as well as every 2 weeks"

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

placebo-controlled medical

"The 52‑week Phase 3 study was a double-blind, placebo-controlled trial in China"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

conjunctivitis medical

"the rate of conjunctivitis, one of the most common side effects of similar products, was not differentiated from placebo"

Inflammation or infection of the conjunctiva, the thin clear tissue that covers the white of the eye and the inside of the eyelid, causing redness, tearing, discharge, itching and light sensitivity—think of it like a rash or sunburn for the eye. For investors it matters because outbreaks or seasonal spikes can change demand for over‑the‑counter remedies, prescription drugs, clinic visits and workplace absences, influencing sales and service volumes for companies in eye care, pharmaceuticals and healthcare services.

il-4 receptor alpha medical

"rademikibart, a next-generation IL-4 receptor alpha blocker with an optimized high affinity binding epitope"

A protein on the surface of certain immune cells that acts like a lock for the signaling molecule interleukin-4; when the lock is engaged it helps drive allergic and inflammatory responses. Investors care because blocking or measuring this receptor is a common strategy for drugs aimed at asthma, eczema and other immune conditions, so changes in clinical trial results, regulatory decisions or competitive positioning around this target can strongly affect a therapy’s market value.

AI-generated analysis. Not financial advice.

– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients –

– Rademikibart was well tolerated with safety comparable to placebo –

– Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting – 

– Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET –

SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced results from a Phase 3 52-week study in patients with moderate‑to‑severe atopic dermatitis (AD) conducted by the Company’s partner in China, Simcere Pharmaceutical Co., Ltd. (Simcere), which were presented during the Late‑Breaking Research session of the 2026 American Academy of Dermatology (AAD) Annual Meeting on March 28, 2026 in Denver, Colorado.

“The results from the RADIANT-AD trial highlight the potential of rademikibart to deliver best-in-class efficacy and safety in AD,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “The positive results demonstrated rapid and durable efficacy data through 52 weeks across key endpoints with favorable safety. Notably, the rate of conjunctivitis, one of the most common side effects of similar products, was not differentiated from placebo in the initial 16-week double-blind induction phase and remained low through 52 weeks. These data, together with our prior Phase 2b 52-week AD study showing that rademikibart administered via subcutaneous (SC) injection every 4 weeks worked as well as every 2 weeks, provide an excellent profile for convenient long-term use and create optionality for us or a future partner to target AD as an indication outside of China.”

Christopher Bunick, M.D., Ph.D., Associate Professor of Dermatology, Yale School of Medicine, added, “Rademikibart's 52-week data in AD presented at the AAD are very encouraging. In particular, the depth and durability of response achieved at week 16 and maintained through one year and low rates of conjunctivitis are impressive, suggesting the potential for rademikibart to be a differentiated treatment option for patients and physicians looking to achieve long-lasting disease control. These clinical results align with the differentiated mechanism of action of rademikibart, a next-generation IL-4 receptor alpha blocker with an optimized high affinity binding epitope.”

RADIANT-AD Study Results
The 52‑week Phase 3 study was a double-blind, placebo-controlled trial in China that enrolled 259 adolescent and adult patients with moderate‑to‑severe AD, who were randomized to receive rademikibart 300 mg administered every two weeks or placebo via SC injection during a 16‑week induction phase, followed by a 36-week maintenance phase in which patients randomized to rademikibart continued on rademikibart and patients randomized to placebo switched to rademikibart. At Week 52, rademikibart demonstrated strong maintenance of response among Week 16 responders, with continued improvement across all key efficacy endpoints.

• Rademikibart demonstrated:
  • 96.6% of patients achieved a ≥75% reduction from baseline in the Eczema Area and Severity Index (EASI‑75);
  • 87.1% of patients achieved a score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction on the Investigator’s Global Assessment of Atopic Dermatitis (IGA 0/1); and
  • 85.3% of patients achieved a ≥90% reduction from baseline in the Eczema Area and Severity Index (EASI‑90).
    

• Rademikibart was well tolerated with safety similar to placebo at 16 weeks and lower conjunctivitis than other agents in the class.
  
  • No significant, drug-related safety issues observed in over 1,500 participants receiving rademikibart in completed studies across indications.
    
    

Company-Hosted Conference Call and Webcast
Connect will host a conference call and webcast today, March 30, 2026, at 8:00 a.m. ET. To access the conference call, please pre-register through here to receive dial-in information and a personal PIN to access the live call. Participants may access the live webcast here or from the Investors section of the Connect website at investors.connectbiopharma.com. An archive of the webcast and presentation will be available for approximately 90 days after the event.

About Rademikibart
Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). We believe that by binding with IL-4Rα, rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the T helper 2 (Th2) inflammatory pathway to achieving the goal of treating Th2-related inflammatory diseases such as atopic dermatitis, asthma and COPD.

About Simcere
Simcere, founded in 1995, is an innovation and R&D-driven pharmaceutical company. The company focuses on the therapeutic areas of neuroscience, oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, fulfilling the mission of “for patients, for life”. Driven by a dual-strategy of in-house R&D and synergistic innovation, Simcere has established strategic cooperation partnerships with multiple innovative biotechs and research institutes.

About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.

For more information visit www.connectbiopharma.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the Act). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our future financial condition, results of operations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), planned or expected product approval applications or approvals, anticipated milestones and royalties, expected data readouts and enrollments, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, anticipated patient populations or market opportunities for our prospective products, if approved, as well as statements regarding industry trends. These statements are based on management’s current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we or our current or future partners will need expanded or additional trials in order to obtain regulatory approval for our product candidates; whether Simcere’s pending NDA for rademikibart in China will receive approval by the National Medical Products Administration (NMPA), and the timing of any such approval; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the People’s Republic of China, Europe and other jurisdictions; the ability of our current cash and investments position to support planned operations; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; and the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community.

Words such as “aim,” “anticipate,” “believe,” “could,” “expect,” “feel,” “goal,” “intend,” “may,” “optimistic,” “plan,” “potential,” “promising,” “will,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results may differ materially due to the risks and uncertainties inherent in our business and other risks described in our filings with the U.S. Securities and Exchange Commission (“SEC”). Further information regarding these and other risks is included under the heading “Risk Factors” in our annual and periodic reports filed with the SEC. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this press release. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date of this press release. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise. Connect Biopharma claims the protection of the safe harbor for forward-looking statements contained in the Act for all forward-looking statements.

This press release discusses our product candidate, rademikibart, which is under clinical investigation and has not yet been approved for marketing by the U.S. Food and Drug Administration, the NMPA, or by any other regulatory agency. No representation is made as to the safety or effectiveness of rademikibart for the uses for which it is being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only.

Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.Lobo@precisionaq.com
(212) 698-8802

Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604

FAQ

What were the key Week 52 efficacy outcomes for rademikibart in the RADIANT-AD Phase 3 trial (CNTB)?

Rademikibart showed strong Week 52 efficacy: EASI-75 96.6%, IGA 0/1 87.1%, EASI-90 85.3%. According to the company, these rates reflect durable responses after a 16-week induction and 36-week maintenance phase in 259 patients.

How did rademikibart's safety compare to placebo and class agents in the Phase 3 RADIANT-AD study (CNTB)?

Safety was comparable to placebo at 16 weeks with low conjunctivitis rates versus peers. According to the company, no significant drug-related safety issues were observed across completed studies involving over 1,500 participants.

What dosing regimen was used for rademikibart in the RADIANT-AD Phase 3 study (CNTB)?

The trial used rademikibart 300 mg administered subcutaneously every two weeks during a 16-week induction, then maintenance through Week 52. According to the company, placebo patients switched to rademikibart during maintenance.

Will Connect Biopharma (CNTB) provide access to the RADIANT-AD Phase 3 presentation and webcast?

Yes. The company hosted a conference call and webcast on March 30, 2026, with an archive available for approximately 90 days. According to the company, the webcast is accessible from the Investors section of its website.

How many patients were enrolled in the RADIANT-AD 52-week Phase 3 trial for rademikibart (CNTB)?

The study enrolled 259 adolescent and adult patients with moderate-to-severe atopic dermatitis. According to the company, patients were randomized to rademikibart 300 mg every two weeks or placebo in the induction phase.

Do the RADIANT-AD results suggest rademikibart may offer dosing convenience for AD patients (CNTB)?

Yes; prior Phase 2b data showed similar efficacy for every-4-week dosing, indicating potential convenience. According to the company, Phase 3 durability and prior results create optionality for less frequent long-term dosing.